Fierce Pharma

JUNE 29, 2023

After an initial rejection in 2020 and a review delay earlier this year, BioMarin’s Roctavian has finally got the FDA go-ahead to introduce a gene therapy for a not-so-rare disorder.

Doctors 320

Doctors FDA 320

MedCity News

AUGUST 25, 2022

Specialty drugs reportedly reached 50 percent of all drug spending in 2020, a figure that has increased significantly over the last decade.

Pharma 336

Pharma Biopharma 336

MedCity News

SEPTEMBER 16, 2024

billion acquisition of Dermira in 2020. Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News.

Competition 317

Competition Pharma FDA Biopharma 317

MedCity News

SEPTEMBER 8, 2022

Medical IoT is forecast to grow from $41 billion in 2020 to $188 billion by 2028. The growth is for a good reason: Connected medical devices, combined with the right software, can improve conditions and delivery, optimize care and devices, and save lives.

Medical 336

Medical 336

MedCity News

MARCH 27, 2023

SR One’s new investment fund is its second one since spinning out of GSK in 2020. The firm says it now has more than $1.5 billion in assets under management.

Management 321

Management Biopharma Pharma 321

Fierce Pharma

NOVEMBER 20, 2024

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. | The spinal muscular atrophy drug is a growth driver for the Swiss pharma giant, prompting the company to prioritize its defense against potential generics.

Medicine 309

Medicine FDA Pharma 309

MedCity News

JANUARY 26, 2023

GPA in 2022, a slight decrease from Leapfrog’s prior survey in 2020, which had a 2.57 From those letter grades, Leapfrog calculated the health plans’ average Grade Point Average (GPA) on a 4.0 Health plans received a 2.29

Insurance 342

Insurance 342

MedCity News

FEBRUARY 20, 2024

But this Phase 2 failure follows the 2020 clinical trial pause of a different partnered molecule that addresses the same target. Sanofi, which is leading development of the Denali Therapeutics-partnered molecule, disclosed little about the clinical trial results in ALS.

Leads 303

Leads Biopharma Pharma 303

MedCity News

MARCH 1, 2024

The deal follows another acquisition WebMD made in the patient engagement space in 2020. WebMD acquired the operating assets of Healthwise, a nonprofit provider of health education content and patient engagement tools.

Patients 314

Patients Education Marketing 314

MedCity News

SEPTEMBER 25, 2022

Pregnancy-related complications increased 9% between 2018 and 2020 among all women, but the rate of change is even more significant among women of color. The disparities exist regardless of having commercial insurance or Medicaid.

Insurance 290

Insurance 290

MedCity News

JANUARY 26, 2023

commercial rollout of the company’s implantable device, which received FDA de novo clearance in 2020. Miach Orthopaedics — a medical device company focused on restoring torn ACLs instead of reconstructing them — recently received $40 million in funding. The capital will be used to expand the U.S.

Medical 299

Medical FDA 299

MedCity News

AUGUST 3, 2022

million people have gained healthcare coverage since 2020. The previous record for the lowest national uninsured rate was 9% in 2016. .

Healthcare 279

Healthcare Healthcare 279

MedCity News

MARCH 31, 2024

Approval of Akebia Therapeutics’ Vafseo is based on additional post-marketing safety data from Japan, where the drug has been used since 2020. The FDA rejected the drug two years ago due to concerns about cardiovascular safety.

FDA 290

FDA Safety Marketing Biopharma 290

MedCity News

OCTOBER 5, 2022

They said it’s important to remember that the mega-boom of 2020 and 2021 was an anomaly for the sector. Digital health’s Q3 saw the lowest quarterly funding total in the past 11 quarters, but experts don’t think this trend should be a cause for concern.

289

289

MedCity News

DECEMBER 21, 2022

Kharraz made a bold declaration about telehealth back in December 2020. In the final episode of 2022, we ask him about that and more.

264

264

Fierce Pharma

DECEMBER 8, 2023

It’s also the first medicine using the revolutionary CRISPR gene-editing system, which earned its inventors a Nobel Prize in 2020 and holds tantalizing potential to cure diseases for which there is no treatment.

FDA 308

FDA Medicine Pharmaceutical 308

Fierce Pharma

DECEMBER 8, 2023

Elizabeth Mily, who replaced BMS’ former M&A czar Paul Biondi back in 2020, is headed for the exit, the company confirmed Friday. Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker. Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker.

280

280

MedCity News

OCTOBER 10, 2022

from 2020 to 2021. EmpiRx found in its data that pharmacy claims for behavioral health treatments increased 9.4% For antidepressants, utilization increased 12% during this time period, but per claim spend fell 1.8%. ADHD medications saw a 20.2% increase in utilization and a 9.1% decrease in per claim spend.

Medical 278

Medical 278

Fierce Pharma

SEPTEMBER 20, 2024

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. That changed Friday.

FDA 207

FDA Patients 207

MedCity News

FEBRUARY 23, 2023

But in 2020, 2021 and 2022, enrollment rose by 1.9 Enrollment in Medicare Advantage plans increased by 5.5% this year, or by 1.5 million beneficiaries, according to The Chartis Group. million, 2.2 million and 2.3 million, respectively.

264

264

MedCity News

APRIL 11, 2023

For more than three-quarters of these hospitals, their spending on charity care and community investment was less than the money they received in tax breaks in 2020. A new report from Lown Institute examined the finances of 1,773 private nonprofit hospitals across the U.S. These combined deficits totaled $14.2

Medical 290

Medical 290

Fierce Pharma

JUNE 26, 2024

The loss of patent protection on Amarin’s sole commercial product Vascepa in 2020 has led to a roller coaster ride for the Dublin-based company over the past few years. Amarin is getting a fresh shot to challenge Hikma Pharmaceuticals’ generic version of its fish oil-derived heart med in the lower courts. business.

Pharmaceutical 243

Pharmaceutical 243

MedCity News

FEBRUARY 6, 2023

ReKlame Health launched in 2020 to provide affordable, culturally competent behavioral healthcare to Black and Brown communities in New York. On Monday, the startup announced it is now serving patients in two additional states — New Jersey and Florida.

Healthcare 246

Healthcare Healthcare Patients 246

Fierce Pharma

APRIL 8, 2024

The FDA refused to accept Supernus' first approval bid after the company acquired the med in 2020. The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump. | The following year, the agency doled out a complete response letter, dashing Supernus' second try.

FDA 248

FDA 248

MedCity News

JULY 24, 2023

In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5% Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025.

Patients 245

Patients FDA Biopharma 245

Fierce Pharma

FEBRUARY 20, 2024

It’s been 15 years since Genzyme began rationing the Fabry disease treatment Fabrazyme after a shortage caused by contamination at a manufacturing site, marking the start of many years of litigatio | Sanofi's Genzyme was accused of causing injuries after contaminated doses of its Fabry disease drug led to a shortage, during which the company rationed (..)

Manufacturing 147

Manufacturing 147

Fierce Pharma

MAY 28, 2024

Since NS Pharma launched its Duchenne muscular dystrophy (DMD) drug Viltepso (viltolarsen) in 2020, sales have steadily

Pharma 199

Pharma Sales 199

Fierce Pharma

OCTOBER 22, 2024

The 2020-approved breast cancer med booked $17.9 MacroGenics’ first commercial product, breast cancer drug Margenza, is heading off to TerSera Therapeutics through a $40 million hand-off. | million in 2023 sales as it struggled to make a mark in the crowded market.

Sales 214

Sales Marketing 214

World of DTC Marketing

AUGUST 26, 2020

However, in both surveys, telehealth visits were perceived as more convenient than office visits (47% in May 2019 vs. 56% in June 2020).

Pharma reps 237

Pharma reps Pharma Rep Doctors Physicians 237

MedCity News

JULY 16, 2023

Q2’s 20 deal marks the highest number of announced transactions for hospitals and health systems since Q1 of 2020. This surge brought Q2’s M&A activity levels in line with those observed before the pandemic.

Healthcare 242

Healthcare Healthcare 242

Fierce Pharma

JUNE 25, 2024

< | The deal with the Israel Tax Authority wraps up pending litigation over taxes payable from 2008 to 2020. With an agreement to make payments totaling $750 million over the next five years, Teva can wipe its slate clean of litigation from Israeli regulators that concerns over a decade's worth of taxes.<

220

220

Fierce Pharma

DECEMBER 20, 2023

In 2020, Palatin Technologies paid $12 million to regain the rights in North America to its struggling female libido drug Vyleesi. | In 2020, Palatin paid $12 million to regain the rights in North America to its struggling female libido drug Vyleesi.

Medicine 196

Medicine Marketing 196

Fierce Pharma

JULY 6, 2023

GSK’s Cabenuva made history in 2020 as the world’s firs | GSK's long-acting Cabenuva is currently approved only as a switch therapy for patients who already have undetectable HIV levels in the blood. Trying to reach some tough populations who have difficulty adhering to existing daily oral therapies, GSK is getting creative.

Patients 226

Patients 226

Fierce Pharma

MAY 16, 2024

After admitting to the crime four years ago, a former Sandoz executive will avoid hard time for his part in a generic drug price-fixing scheme. | Hector Kellum agreed to cooperate with federal investigators in 2020, admitting his part in a massive generics price-fixing scheme that spanned many companies.

196

196

World of DTC Marketing

OCTOBER 21, 2020

2020 trend concept. Hand flip wood cube change year 2019 to 2020. In my opinion, this is due to pharma being sold on programmatic and the lack of investment in creative. 9ine: Searches for specific medical terms have increased, indicating that people don’t necessarily understand common medical terms.

Media 287

Media Pharma Medical Safety 287